| Title |
Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, April 2013
|
| DOI | 10.2147/dmso.s28951 |
| Pubmed ID | |
| Authors |
Eleonora Russo, Giuseppe Penno, Stefano Del Prato |
| Abstract |
Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified oral anti-diabetic drugs for the treatment of type 2 diabetes mellitus (T2DM) that provide important reduction in glycated hemoglobin, with a low risk for hypoglycemia and no weight gain. In T2DM patients with reduced renal function, adequate glycemic control is essential to delay the progress of kidney dysfunction, but they are at a greater risk of experiencing hypoglycemic events, especially with longer-acting sulfonylureas and meglitinides. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 1% |
| Russia | 1 | 1% |
| Unknown | 94 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 17 | 18% |
| Researcher | 15 | 16% |
| Other | 11 | 11% |
| Student > Ph. D. Student | 11 | 11% |
| Student > Postgraduate | 9 | 9% |
| Other | 17 | 18% |
| Unknown | 16 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 53% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 10% |
| Nursing and Health Professions | 5 | 5% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Unspecified | 3 | 3% |
| Other | 5 | 5% |
| Unknown | 18 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2013.
All research outputs
#14,657,623
of 25,457,858 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#409
of 1,184 outputs
Outputs of similar age
#114,185
of 213,192 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#3
of 5 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,192 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.